Shopping Cart
- Remove All
- Your shopping cart is currently empty
Antitumor agent-171 (Compound 35) acts as an inhibitor of the β-catenin/BCL9 interaction, with an IC50 of 1.61 μM. It suppresses the expression of the axin2 gene, demonstrating an IC50 value of 0.84 μM, and exhibits high affinity for β-catenin with a Kd of 0.63 μM. Additionally, Antitumor agent-171 inhibits the viability of HCT116 cells with an IC50 of 4.39 μM. It activates T cells, enhances antigen presentation, and shows antitumor activity and favorable pharmacokinetic properties in murine models.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | Antitumor agent-171 (Compound 35) acts as an inhibitor of the β-catenin/BCL9 interaction, with an IC50 of 1.61 μM. It suppresses the expression of the axin2 gene, demonstrating an IC50 value of 0.84 μM, and exhibits high affinity for β-catenin with a Kd of 0.63 μM. Additionally, Antitumor agent-171 inhibits the viability of HCT116 cells with an IC50 of 4.39 μM. It activates T cells, enhances antigen presentation, and shows antitumor activity and favorable pharmacokinetic properties in murine models. |
Molecular Weight | 643.78 |
Formula | C35H45N7O5 |
Cas No. | 3003004-76-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.